This CX Programme is subject to change.
Peripheral Proximal Arterial Ischaemia Challenges - Tuesday, 16th April
Venue: Upper Main Auditorium
Time: 08:00 - 18:00
Peripheral arterial disease issues
| Chairing: | Cliff Shearman, Southampton, United Kingdom |
| Moderator: | Barry Katzen, Miami, United States |
08:00 - 08:08
Treatment of claudication is aimed to increase walking distance, improve quality of life and prevent cardiovascular events by reducing risk factors
| Speaker: | Sanne Klaphake, Rotterdam, Netherlands |
08:08 - 08:16
Female gender is a risk factor for poor outcomes after revascularisation for peripheral arterial disease
| Speaker: | Ruth Benson, Birmingham, United Kingdom |
08:16 - 08:24
Audience participation and discussion
08:24 - 08:32
Office-based lower extremity arterial interventions are feasible, safe, cost-effective and patients love it
| Speaker: | Enrico Ascher, Brooklyn, United States |
08:32 - 08:40
Ambulatory treatment of arterial disease - European perspective
| Speaker: | Yann Gouëffic, Nantes, France |
08:40 - 08:48
Audience participation, discussion and polling
08:48 - 08:56
Appropriate follow-up of patients after endovascular procedures
| Speaker: | Marianne Brodmann, Graz, Austria |
08:56 - 09:04
Open or endovascular repair for popliteal artery aneurysms - A case-control study
| Speaker: | Martin Björck, Uppsala, Sweden |
09:04 - 09:12
Audience participation and discussion
Imaging
| Chairing: | Robert Morgan, President CIRSE, London, United Kingdom |
| Moderator: | Andrew Holden, Auckland, New Zealand |
09:12 - 09:20
Assessment of the perfusion with indocyanine green fluorescence imaging (ICG-FI) before and after revascularisation tells the success of revascularisation
| Speaker: | Maarit Venermo, Helsinki, Finland |
09:20 - 09:28
Tips and tricks to optimise CO2 angiography (including work-up with no-contrast MR angiography)
| Speaker: | Jos van den Berg, Lugano, Switzerland |
09:28 - 09:36
Audience participation and discussion
09:36 - 09:44
IVUS sizing improves outcomes of DCB therapy in the femoropopliteal segment
| Speaker: | Phillip Puckridge, Marion, Australia |
09:44 - 09:52
Contrast-enhanced tomographic 3D ultrasound imaging of peripheral arterial disease and potential autologous bypass grafts
| Speaker: | Steven Rogers, Manchester, United Kingdom |
09:52 - 10:00
Audience participation, discussion and polling
Coffee and visit to hands-on workshops
Time: 10:00 - 10:30
Coffee Symposium: The paclitaxel safety controversy - from patient-level data to big data: What the newest clinical evidence is telling us
Time: 10:03 - 10:28
| Chairing: | Peter Schneider, Honolulu, United States |
| Moderator: | Giovanni Torsello, Münster, Germany |
10:03 - 10:09
Patient-level data from the IN.PACT Clinical Programme: Is paclitaxel safe for the treatment of PAD?
| Speaker: | Peter Schneider, Honolulu, United States |
10:09 - 10:15
Two-year outcomes from four pooled multicentre RCTs: Safety after treatment with paclitaxel-coated balloons
| Speaker: | Thomas Albrecht, Berlin, Germany |
10:15 - 10:21
Big data: What does it tell us about survival following PAD revascularisation using drug technologies?
| Speaker: | Eric Secemsky, Boston, United States |
10:21 - 10:28
Audience participation and discussion
Paclitaxel debate
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Thomas Zeller, Bad Krozingen, Germany |
10:30 - 10:40
CX Debate: DCB alone is enough for the popliteal segment
For the motion
10:30 - 10:35
| Marc Bosiers, Dendermonde, Belgium |
Against the motion
10:35 - 10:40
| Theodosios Bisdas, Athens, Greece |
10:40 - 10:50
Audience participation, discussion and polling
Paclitaxel: The last word
| Chairing: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Gunnar Tepe, Rosenheim, Germany | |
| Thomas Zeller, Bad Krozingen, Germany |
Review of the findings of the VIVA Forum
10:50 - 11:00
Paclitaxel summary of VIVA
| Speaker: | Gary Ansel, Columbus, United States |
11:00 - 11:10
Audience participation, discussion and polling
The potential problem
11:10 - 11:20
My choices of DCB and DES data to combine in meta-analysis and my conclusions
| Speaker: | Konstantinos Katsanos, Patras, Greece |
11:20 - 11:27
BASIL 3 - withdrawal of paclitaxel use
| Speaker: | Jonathan Michaels, Sheffield, United Kingdom |
11:27 - 11:34
SWEDEPAD trials - withdrawal of paclitaxel use
| Speaker: | Marten Falkenberg, Gothenburg, Sweden |
11:34 - 11:50
Audience participation, discussion and polling
Scrutiny of paclitaxel and the way forward
11:50 - 12:00
Statistical review of methodology and legitimacy of results
| Speaker: | Sue Duval, Minneapolis, United States |
12:00 - 12:10
Statistical issues
| Speaker: | Jon Deeks, Birmingham, United Kingdom |
12:10 - 12:30
Audience participation, discussion and polling
Lunch and visit to hands-on workshops
Time: 12:30 - 13:30
Lunch Symposium: Optimising DCB results for long-term success
Time: 12:33 - 12:58
| Chairing: | Michael Lichtenberg, Arnsberg, Germany |
| Moderator: | Gary Ansel, Columbus, United States |
12:33 - 12:41
Long-term safety and efficacy update of a low-dose DCB
| Speaker: | Gary Ansel, Columbus, United States |
12:41 - 12:49
The benefits of IVUS in DCB treatment of the femoropopliteal segment
| Speaker: | Phillip Puckridge, Marion, Australia |
12:49 - 12:58
The value of effective vessel preparation before DCB use
| Speaker: | Theodosios Bisdas, Athens, Greece |
Review of paclitaxel usage: The way forward
| Chairing: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Gunnar Tepe, Rosenheim, Germany | |
| Thomas Zeller, Bad Krozingen, Germany |
13:30 - 13:38
What the FDA are looking for in data requested
| Speaker: | Misti Malone, Silver Spring, United States |
13:38 - 13:46
What MHRA are looking for
| Speaker: | Hazel Randall, London, United Kingdom |
13:46 - 13:56
Audience participation, discussion and polling
13:56 - 14:04
Paclitaxel early advances to limit restenosis
| Speaker: | Ulrich Speck, Berlin, Germany |
14:04 - 14:12
Paclitaxel: Why a chemotherapeutic was chosen to prevent restenosis - rationale and early experience
| Speaker: | Lindsay Machan, Vancouver, Canada |
14:12 - 14:20
Paclitaxel as primary therapy in oncology - benefits, doses, levels compared
| Speaker: | Erica Mayer, Boston, United States |
14:20 - 14:35
Audience participation, discussion and polling
14:35 - 14:43
Lessons learned from the experience in the coronary arteries - sirolimus, paclitaxel and everolimus
| Speaker: | Bruno Scheller, Homburg, Germany |
14:43 - 14:51
Potential toxicity of paclitaxel in vascular interventions and pharmacokinetic aspects
| Speaker: | Aloke Finn, Gaithersburg, United States |
14:51 - 14:59
Paclitaxel effects on the human artery wall and insights from pathology
| Speaker: | Elena Ladich, Hollywood, FL, United States |
14:59 - 15:30
Audience participation, discussion and polling
Tea and visit to hands-on workshops
Time: 15:30 - 16:00
Tea Symposium: Aortoiliac obstructive disease: Endoluminal solutions
Time: 15:33 - 15:58
| Chairing: | Michele Antonello, Padua, Italy |
15:33 - 15:39
Complexity of iliac occlusive disease, current treatment algorithm and treatment gaps
| Speaker: | Michele Antonello, Padua, Italy |
15:39 - 15:45
Challenging bilateral iliac case treated with a new balloon-expandable endoprosthesis
| Speaker: | Hany Zayed, London, United Kingdom |
15:45 - 15:51
Complex iliac occlusive disease: Treatment with covered stent grafts
| Speaker: | Gianmarco de Donato, Siena, Italy |
15:51 - 15:58
Audience participation and discussion
Edited case
| Chairing: | Michele Antonello, Padua, Italy |
16:00 - 16:30
Edited case: Treating iliac occlusive disease with a covered endoprosthesis
| Case presenter: | Andrew Holden, Auckland, New Zealand |
Interventional techniques
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Robert Hinchliffe, Bristol, United Kingdom |
16:30 - 16:37
Advantages and results of treating SFA-popliteal occlusive lesions with a dual component stent: From the Austrian Registry
| Speaker: | Martin Werner, Vienna, Austria |
16:37 - 16:44
How to treat in-stent-restenosis in the femoropopliteal tract - what the literature tells us
| Speaker: | Marc Bosiers, Dendermonde, Belgium |
16:44 - 16:51
The case for spot stenting - similarities and differences between techniques
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
Edited case
16:51 - 17:21
Edited case: Focal dissection repair after femoropopliteal angioplasty
| Case presenter: | Michael Lichtenberg, Arnsberg, Germany |
17:21 - 17:28
Femoropopliteal bypasses with heparin-bonded PTFE are a durable treatment for long SFA-popliteal occlusions: When they are the best treatment and why
| Speaker: | Walter Dorigo, Florence, Italy |
17:28 - 17:40
Audience participation and discussion
Open bypass
17:40 - 17:50
CX Debate: In the absence of suitable venous graft material prosthetic bypass is the answer
For the motion
17:40 - 17:45
| Clement Darling III, Albany, United States |
Against the motion
17:45 - 17:50
| Andrew Holden, Auckland, New Zealand |
17:50 - 18:00
Audience participation, discussion and polling